Tratamiento del trastorno obsesivo-compulsivo resistente: Una actualizacion

Actas Espanolas de Psiquiatria

Volumn 25, Issue 1, 1997, Pages 61-69

  Crespo Facorro, B ^a   Gomez Hernandez R ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Resistant obsessive compulsive disorder; Treatment; Up date

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; HUMAN; OBSESSIVE COMPULSIVE DISORDER; REVIEW; TIC;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONOAMINE OXIDASE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TIC DISORDERS;

EID: 2842536946     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Bland RC, Newman SC, Orn H. Period prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand 1988; 77 (suppl. 338): 33-42.
2. Karno M, Goldin JM, Soreman SB, Burnam A. The epidemiology of Obsessive-Compulsive Disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094-9.
3. Myers JK, Weissman MM, Tischler JL, et al. Six month of prevalence of psychiatric disorder in three commitments. Arch Gen Psychiatry 1984; 41: 949-58.
4. Griest JH. An integrated approach to treatment of obsessive-compulsive disorder. J Clin Psychiatry 1992; 53 (suppl. 4): 38-41.
5. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry 1992; 53 (suppl. 4): 29-37.
6. Livingston-Van Noppen B, Rasmusen SA, Eisen J, et al. Family function and treatment of obsessive-compulsive disorder. En: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. Mass, PSG publishing, Littleton, 2nd ed. 1990: 325-40.
7. Baxter LR Jr, Schwartz JM, Mazziotta IM, et al. Cerebral glucose metablolisc rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1560-3.
8. Rauch SL, Jenike MA, Alpert NM, et al. Regional blood flow measured during symptom provocation in obsessive compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994; 51: 62-70.
9. McGuire PK, Bench CJ, Frith CD, et al. Functional anatomy of obsessive compulsive phenomena. Br J Psychiatry 1994; 164: 459-68.
10. Jenike MA y Rauch SL. Managing the patient with treatment resistant obsessive-compulsive disorder: Current strategies. J Clin Psychiatry 1994; 55 (suppl. 3): 11-7.
11. Tamimi RR y Mavissakalian MR. Are effective antiobsessional drugs interchangeable? [letter]. Arch Gen Psychiatry 1991; 48: 857-8.
12. Pigott TA, Murphy DL. Respuesta a «Are effective antiobsessional drugs Interchangeable? [letter]. Arch Gen Psychiatry 1991; 48: 858-9.
13. Montgomery S. Clomipramine in obsesional neurosis: A placebo-controlled trial. Pharmaceutical Med 1980; 1: 189-92.
14. López-Ibor Aliño y cols.: Trastorno obsesivo-compulsivo y depresión. Actas Luso-Españolas de Neurología, Psiquiatría y Ciencias Afines. 1995; 23: 97-113.
15. Barcia D. Comorbilidad, depresión y trastorno obsesivo-compulsivo. Actas Luso-Españolas de Neurología, Psquiatría y Ciencias Afines. 1996; 24: 91-6.
16. Griest J, Jefferson J, Rosenfeld R, et al. Clomipramine and obsesive-compulsive disorder: A placebo-controlled double-blind study of 32 patients. J Clin Psychiatry 1990; 51: 292-7.
17. Minichiello WE, Baer L, Jenike M. Schizotypal personality disorder: A poor prognostic indicator for behavioral therapy in the treatment of obsessive-compulsive disorder. J Anxiety Disord 1987; 1: 273-6.
18. Baer L, Jenike MA, Black DW, et al. Effects of Axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 862-6.
19. Jenike MA, Baer L, Minichiello WE, et al. Concomitant obsessive-compulsive disorder and schizotyal personality disorder. Am J Psychiatry 1986; 143: 530-2.
20. Katz RJ, De Veaugh-Geiss J. The antiobsessional effects of clomipramine do not require concomitant affective disorder. Psychiatry Res 1980; 31: 121-9.
21. Mavissakalian M, Turner SM, Michelson L, et al. Tricyclic antidepressant in obsessive-compulsive disorder: antiobsessional or antidepressant agent? II. Am J Psychiatry 1985; 142: 572-6.
22. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and relibiality. Arch Gen Psychiatry 1989; 48: 1006-11.
23. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive-Compulsive Scale, II: validity. Arch Gen Psychiatry 1989; 46: 1012-6.
24. Marks IM. Review of behaviour psychotherapy; I: obsessive Compulsive disorders. Am J Psychiatry 1981; 138: 584-92.
25. Marks IM, Lelliot P, Basoglu M, et al. Clomipramine, self expousure and therapist aided exposure in obsessive compulsive ritualisers. Br J Psychiatry 1988; 152: 522-34.
26. Cottraux J, Mollard E, Bourard M, et al. A controlled study of Fluvoxamine and exposure in obsessive compulsive disorder. Int Clin Psychopharmacol 1990; 5: 17-30.
27. Ost LG. A maintance programe for the behavioural treatment of anxiety disorders. Behav Res Ther 1989; 27: 123-30.
28. Kasvikis Y, Marks IM. Clomipramine, self-exposure and therapist-accompanied exposure in obsessive compulsive ritualizers: 2-years follow-up. J Anxiety Disorders 1988; 2: 291-8.
29. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. Am J Psychiatry 1984; 141: 1283-5.
30. Mattes JA. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1986; 1: 170-3.
31. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986; 21: 1067-71.
32. Judd FK, Chua P, Lynch, et al. Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder. Aust NZ J Psychiatry 1991; 25: 412-4.
33. Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990; 51: 119-23.
34. Kleven MS y Seiden LS. d-, 1- and dl-femfluramine cause long-lasting depletions of serotonin in rat brain. Brain Res 1989; 505: 351-3.
35. Price LH, Ricaurte GA, Krystal JH, et al. Neuroendocrine and mood responsos to intravenous 1-tryptophan in 3,4-methylenedioxy-methamphetamine (MDMA) users: preliminary observations. Arch Gen Psychiatry 1989; 46: 20-2.
36. Goodman WK, McDougle CJ, Barr LC, Aronson SC, et al. Biological approaches to Treatment-Resistant obsessive-compulsive disorder. J Clin Psychiatry 1993; 54 (6): 16-26.
37. Blier P, De Montigny C. Lack of efficacy of lithium augmentation in obsessive-compulsive disorder: the perspective of different regional effects of lithium on serotonin release in the central nervous system. J Clin Psychopharmacol 1992; 12: 65-6.
38. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepresant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1938; 40: 1335-42.
39. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175-84.
40. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11: 241-8.
41. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine resistant obsessive compulsive disorder. Am J Psychiatry 1984; 141: 1283-5.
42. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 798-800.
43. Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 1991; 52: 13-4.
44. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 11-8.
45. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 647-9.
46. Tanquary J, Masand P. Paradoxical reaction to buspirone augmentation of fluoxetine. J Clin Psychopharmacol 1990; 10: 377.
47. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 420-30.
48. Wagner HR, Reches A, Yablonskaya E, et al. Clonazepam induced up-regulation of serotonin-1 and serotonin-2 binding sites in rat frontal cortex. Adv Neurol 1986; 43: 645-51.
49. Pratt J, Jenner P, Reynolds EH, et al. Clonazepam induces decreased serotoninergic activity in the mouse brain. Neuropharmacology 1979; 18: 791-9.
50. Hwang EC, Van Woert MH. Antimyoclonic action of clonazepam: the role of serotonin. Eur J Pharmacol 1979; 60: 31-40.
51. Hewlett WA. The use of benzodiazepines in obsessive-compulsive disorder and Tourette's syndrome. Psychiatric Annals 1993; 23: 309-16.
52. Bacher NM. Clonazepam treatment of obsessive-compulsive disorder (letter). J Clin Psychiatry 1990; 51: 168-9.
53. Bodkin JA, White K. Clonazepam in the treatment of obsessive-compulsive disorder asociated with panic disorder in one patient. J Clin Psychiatry 1989; 50: 265-6.
54. Jenike MA. Drug treatment of obsessive-compulsive disorder. En: Jenike MJ, Baer I, Minichiello WE, eds. Obsessive Compulsive Disorders: Theory and management. 2nd ed. Mass: PSG Publising, Little-ton. 1990: 249-82.
55. Hollander E, Mullen L, DeCaria CM, et al. Obsessive-compulsive disorder, depression and fluoxetine. J Clin Psychiatry 1991; 52: 418-22.
56. Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsesive-compulsive disorder with clomipraminefluoxetine combination. Psychopharmacol Bull 1990; 26: 285-90.
57. Rosenstein DL, Takeshita J, Nelson JC. Fluoxetine induced elevation and prolongation of tricyclic levels in overdose. Am J Psychiatry 1991; 148: 807.
58. Jenike MA. management the patients with treatment resistant obsessive-compulsive disorder. En: Pato MT, Zohar J, eds. Obsessive Compulsive Disorder. Washington, DC: American Psychiatry Association, 1991: 135-56.
59. Jenike MA. Approaches to the patient with treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 1990; 51 (2): 15-21.
60. Piggot TA, L'Heureux F, Rubinstein CS, et al. Double blind, placebo controlled study of trazodone in patient with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 156-62.
61. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46: 722-30.
62. Phillips KA. Body dysmorphic disorder: the distress of imaged uglyness. Am J Psychiatry 1991; 148: 1138-49.
63. Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 1991; 52: 221-33.
64. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine refractory obsessive compulsive disorder. Am J Psychiatry 1990; 147: 652-4.
65. Stein DJ, Hollander E. Low dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992; 53: 123-6.
66. Delgado PL, Goodman WK, Price LH, et al. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive compulsive disorder. Br J Psychiatry 1990; 157: 762-65.
67. Isberg RA. A comparion of phenelzine and imipramine in an obsessive-compulsive patient. Am J Psychiatry 1981; 138: 1250-1.
68. Jenike M. MAOI for Obsessive-compulsive disorder. Am J Psychiatry 1981; 138: 1249-50.
69. Vallejo J, Olivares J, Marcos T, Bulbene A, Menchon JM. Clomipramine versus phenlelzine in obsessive-compulsive disorder: A controlled clinical trial. Br J Psychiatry 1992; 161: 665-70.
70. Jenike MA, Surman OS, Casem NH, et al. Monoamine oxidase inhibitors in obsessive compulsive disorder. J Clin Psychiatry 1983; 144: 131-2.
71. Fallon BA, Campeas R, Schneier FR, et al. Open trial intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 70-5.
72. Warneke LB. Intravenous Clomipramine therapy in obssive compulsive disorder. Can J Psychiatry 1989; 34: 853-9.
73. Thakur AK, Remillard AJ, Meldrum LH, et al. Intravenous clomipramine and obsessive-compulsive disorder. Can J Psychiatry. 1991; 36: 521-4.
74. López-Ibor Aliño JJ. 1969. Intravenous perfusions of monochiorimipramine Technique and results. En: Cerletti A, Bove, FJ (Eds). The present status of psychotropic drugs. Amsterdam: Experta Medica.
75. Cohen DJ, Detlor J, Young JG, et al. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37: 1350-7.
76. Hollander E, Fay M, Cohen B, et al. Serotonic and noradrenergic sensitivity in obsesive-compulsive disorder: behavioral findings. Am J Psychiatry 1988; 145: 1015-7.
77. Knesevich JW. Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride. Am J Psychiatry 1982; 139: 364-5.
78. Lipsedge MS, Prothero W. Clonidine and clomipramine in obsessive compulsive disorder. Am J Psychiatry 1987; 144: 965-6.
79. Joffe RT, Swinson RP. Carbamazepine in obsesive-compulsive disorder. Biol Psychiatry 1987; 22: 1169-71.
80. Khanna S. Carbamazepine in obsessive-compulsive disorder. Clin Neuropharmacol 1988; 11: 478-81.
81. Jenike MA, Brotman AW. The EEG in obsessive-compulsive disorder. J Clin Psychiatry 1984; 45: 122-4.
82. McElroy SL, Keck PE Jr, Pope HG Jr. Sodium Valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16-24.
83. Insel TR, Hamilton JA, Guttmacher LB, et al. D-Anphetamin in obsessive-compulsive disorder. Psychopharmacology 1983; 80: 231-5.
84. Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol. 1991; 1: 237-41.
85. Swinson RP, Joffe RT. Biological challenges in obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 369-75.
86. Lemus CZ, Robinson DG, Kroniq M, et al. Behavioral responses to a dopaminergic challenge in obsessive-compulsive disorder. J Anxiety Disord 1991; 5: 369-73.
87. Borcherding BG, Keysor CS, Rapoport JL, et al. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 1990; 33: 83-94.
88. Koizumi KM. Obsessive compulsive symtoms following stimulants. Biol Psychiatry 1985; 20: 1332-3.
89. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive-compulsive disorder? J Clin Psychiatry 1990; 5 (suppl): 36-45.
90. Frye PE, Arnold LE. Persistent amphetamine-induced compulsive rituals: response to pyridoxine (B6). Biol Psychiatry 1981; 16: 583-7.
91. Young CR, Bostic JQ, McDonald CL. Clozapine and refractory obsessive compulsive disorder: A case report. J Clin Psychopharmacol 1994; 14: 209-11.
92. McDougle CJ, Barr LC, Goodman WK, Penton GH, et al. Lack of efficacy of Clozapine monotherapy in refractor obsessive compulsive disorder. Am J Psychiatry 1995; 152: 1812-4.
93. Baker RW, Chengappa KNR, Baid JW, et al. Emergence of Obsessive compulsive symtoms during treatment with clozapine. J Clin Psychiatry 1992; 53: 439-42.
94. Patil VJ. Development of transient obsessive-compulsive symtoms during treatment with clozapine (letter). Am J Psychiatry 1992; 149: 272.
95. Casas M, Alvarez E, Duro P, et al. Antiandrogenic treatment of obsessive compulsive neurosis. Acta Psychiatr Scand 1986; 73: 221-2.
96. Insel TR. Oxiyocin -a neuropeptide for affiliation: evidence from behavioral, receptor autoradiographic, and comparative studies. Psychoneuroendocrinology 1992; 17: 335.
97. Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 1987; 12: 231-6.
98. Rojo Sierra M, Seva Díaz A. El LSD-25 en psicoterapia de los estados obsesivos. Rev Actualidad Médica 1965; Abril.
99. Seva Díaz A. Investigaciones en torno al fenómeno obsesivo. Actas Luso-Españolas de Neurología y Psiquiatría 1964; XXIII (4).
100. Mellman LA, Gorman JM. Sucessful treatment of obsessive-compulsive disorder with ECT. Am J Psychiatry 1984; 48: 48-555.
101. Chiocca EA, Martuza RL. Neurosurgical therapy of obsessive-compulsive disorder. En: Jenike MA, Baer L, Minichiello W, eds. Obsessive-Compulsive Disorders: Theory and management, Chicago: 1990; 283-294.
102. Mindus P, Jenike MA. Neurosurgical treatment of malignat obsessive-compulsive disorder. En: Jenike MA,. Psychiatric Clinics of North America: obsessional Disorders. Philadelphia: Saunders ed. 15 (4) 1992: 921-38.
103. Corkin S, Twitchell TE, Sullivan EV. Safety and eficacy of cingulotomy for psychiatric disorder. En: Hitchcock ER, Ballantine HT, Myerson BA, eds. Modern Concepts in Psychiatric Surgery. Amsterdam: Elsevier Science, 1979: 253-72.
104. Jenike MA, Baer L, Ballantine HT, et al. Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow-up of 33 patients. Arch Gen Psychiatry 1991; 48: 548-55.
105. Joffe RT, Swinson RP. Total sleep deprivation in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 1988; 77: 483-7.
106. Yoney TH, Pigott TA, L'Heureux, et al. Seasonal variation in obsessive-compulsive disorder: preliminary experience with light treatment. Am J Psychiatry 1991; 148: 1727-9.